Logo

LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis

Share this
LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis

LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis

Shots:

  • The P-III ECZTRA 6 trial evaluates the efficacy & safety of tralokinumab (150/300mg- q2w) as monothx. vs PBO in 301 patients aged 12-17yrs. with mod. to sev. AD who were candidates for systemic therapy
  • The trial met its 1EPs & 2EPs i.e.- @16wks.- patients achieved a clinical response & achieved clear or almost clear skin as measured by IGA (21.4%/17.5% vs 4.3%); ≥75% disease improvement from baseline (28.6%/27.8% vs 6.4%) as measured by EASI
  • In 2EPs- patients achieved 4-point improvement in adolescent weekly average worst daily pruritus NRS score & health-related QoL related to dermatological conditions. The therapy was well-tolerated with an overall frequency & severity of AEs

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Berlingske


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family